Afasevikumab

Modify Date: 2024-01-02 12:36:28

Afasevikumab structure	Common Name	Afasevikumab
	CAS Number	1589503-30-9	Molecular Weight	N/A
	Density	N/A	Boiling Point	N/A
	Molecular Formula	N/A	Melting Point	N/A
	MSDS	N/A	Flash Point	N/A

Use of Afasevikumab

Afasevikumab (RG 7624; RO 5553110; NI-1401) is a fully human monoclonal IgG1κ antibody neutralizing both IL-17A and IL-17F. Afasevikumab has anti-inflammatory activities[1].

Name	Afasevikumab

Description	Afasevikumab (RG 7624; RO 5553110; NI-1401) is a fully human monoclonal IgG1κ antibody neutralizing both IL-17A and IL-17F. Afasevikumab has anti-inflammatory activities[1].
Related Catalog	Signaling Pathways >> Immunology/Inflammation >> Interleukin Related Research Areas >> Inflammation/Immunology
In Vitro	Afasevikumab 由 N 末端 IL-17F 特异性部分、结合 IL-17A 和 IL-17F 的 a-C 末端部分以及结合人血清白蛋白的中心部分组成[1]。
References	[1]. Andrea Chiricozzi, et al. Emerging treatment options for the treatment of moderate to severe plaque psoriasis and psoriatic arthritis: evaluating bimekizumab and its therapeutic potential. Psoriasis (Auckl). 2019 May 24;9:29-35.

No Any Chemical & Physical Properties